Compounded GLP-1: What It Means, Rules and Risks Explained

It's 11pm, you've got three tabs open, and one word keeps tripping you up: 'compounded.' A compounded GLP-1 is a semaglutide or tirzepatide medicine that a pharmacy prepares for one patient from a clinician's prescription, and unlike a drug company's product, the FDA doesn't approve or review it.^[1][2]

That single difference changes how the medicine is regulated, what has been studied, and which questions are worth asking. Let's sort it out in plain English, including the part where the rules have shifted over the past two years.

The short version

• 'Compounded' means a pharmacy prepares the medicine for one patient from a prescription. It isn't FDA-approved, and the FDA doesn't review it for safety, effectiveness or quality before patients get it.^[2]
• The rules tightened after the FDA ended the semaglutide and tirzepatide shortages. The FDA now says compounded drugs should be used only when an approved drug can't meet a patient's medical needs.^[1][4]
• The headline weight-loss results come from trials of FDA-approved products, not compounded ones, and individual results may vary.^[7]
• Side effects are mostly stomach-related, approved labels carry a boxed warning, and a licensed clinician decides whether any of this fits you.^[6][8]

What does compounded GLP-1 mean, exactly?

It means a licensed pharmacy makes a GLP-1 medicine, usually semaglutide or tirzepatide, for one named patient after a clinician writes a prescription for that person.^[2] That patient-specific prescription is one of the legal conditions for this kind of compounding.^[2]

Think of a packaged loaf on a supermarket shelf versus a cake a baker makes to order. Both are real food. But the loaf went down a standardized line, while the cake was made for one customer.

Medicines work the same way. Approved drugs go through FDA review before they're sold. Compounded ones don't.^[2]

Semaglutide and tirzepatide are the two ingredients people usually mean by 'GLP-1 medicine.' If you want the how-does-it-make-me-feel-full version, our explainer on what GLP-1 is covers it. Here, we're after a different question: what does the word 'compounded' actually change?

How is a compounded GLP-1 different from the FDA-approved version?

The biggest difference is review: the FDA checks approved drugs for safety, effectiveness and quality before they're sold, and it doesn't do that for compounded drugs.^[2] Here's how that plays out side by side.

Question	FDA-approved branded product	Compounded GLP-1 (503A pharmacy)
FDA review for safety, effectiveness and quality before sale?	Yes	No[2]
Made for	Wide distribution by a manufacturer	One identified patient, from a valid prescription[2]
Label with directions for use	FDA-approved label	Not required to have one[2]
Manufacturing standards	Must meet current good manufacturing practice	Not required to meet them under 503A[2]
Studied in the big weight-loss trials	Yes	No[7]

Two of those rows deserve a plain translation. A 503A pharmacy doesn't have to follow the same manufacturing rules a drug company does.^[2] And federal law doesn't require state-licensed pharmacies like these to report adverse events to the FDA, so problems are likely underreported.^[1]

So a compounded drug is not a generic version of a brand-name drug, and it isn't 'the same' as one. In fact, the FDA lists claims that a compounded drug is the same as an FDA-approved drug as a telehealth red flag.^[1]

Does that make compounded medicine automatically bad? No. The FDA says compounded drugs can serve an important role for patients whose needs an approved drug can't meet.^[3] But it also says they pose a higher risk than approved drugs, because they don't get FDA review before they're marketed.^[5] Which brings us to why this topic is suddenly everywhere.

Why is everyone arguing about compounded GLP-1s right now?

Because the rules changed: pharmacies could make copies while the approved drugs were in short supply, and that window has closed.^[4][5]

Normally, compounding a drug that's already commercially available isn't permitted.^[3] When a drug is on the FDA's shortage list, compounders may be able to make a version of it if they meet certain conditions.^[5] The FDA decided the tirzepatide shortage was resolved on December 19, 2024, and the semaglutide shortage on February 21, 2025.^[4]

Since then, the FDA's tone has sharpened. It has raised concerns about dosing errors, improper storage during shipping and fraudulently labeled products.^[1] It also says some compounders use semaglutide salt forms, which are different active ingredients from the approved drugs, and it isn't aware of any lawful basis for that.^[1]

Here's one more detail worth knowing. The FDA says retatrutide and cagrilintide can't be used in compounding under federal law, and they haven't been found safe or effective for any condition.^[1] If anyone offers you those, treat it as a stop sign.

So where does that leave a compounded GLP-1 today? That depends on a very specific question.

When might a clinician consider a compounded GLP-1 for a patient?

The FDA's position is that compounded drugs should be used only in patients whose medical needs can't be met by an FDA-approved drug.^[1] Its own examples are practical ones, like a patient with an allergy who needs a medicine made without a certain dye, or an older patient who can't swallow a pill.^[3]

There's also a paperwork side. If a compounded drug has the same active ingredient, a similar strength and the same route as an approved one, the FDA generally treats it as 'essentially a copy.' The exception is when the prescriber determines it produces a significant difference for that individual patient, and documents it on the prescription.^[3]

In plain words: the clinician needs a real, patient-specific reason, and writes it down. Whether you fit that picture is their call, not yours and not a blog's.

What you can do is show up with good questions:

• What is the specific reason a compounded version fits me, instead of an approved product?
• Does my history raise any flags, such as thyroid cancer in my family, pancreas or gallbladder trouble, pregnancy plans, or diabetes medicines?^[6][8]
• Which state-licensed pharmacy prepares it, and will I get written directions? A label with directions isn't required for this kind of compounding.^[1][2]
• How do I measure and give my dose, how should I store it, and what do I do if it arrives warm or damaged?^[1]
• Who do I call if I feel unwell, and what counts as urgent?

Your own doctor or pharmacist can also walk you through approved options and how your coverage works. Now, what does the research actually say?

What do the weight-loss trials tell us about compounded GLP-1s?

Not much directly, because the big trials studied FDA-approved branded products, and compounded versions were not studied.

Take STEP 1, a trial published in the New England Journal of Medicine. Adults with overweight or obesity, but without diabetes, took semaglutide 2.4 mg once a week or a placebo for 68 weeks, and both groups also got lifestyle support.^[7]

On average, the semaglutide group lost 14.9% of their starting body weight, versus 2.4% on placebo.^[7] That's roughly 15 pounds for every 100 pounds someone started with.

More people on semaglutide lost at least 5% of their weight: 83.5% versus 31.1% on placebo, in the label's account of that trial.^[6] These are group averages, so individual results may vary, and some people lose more and some less. The trial was also funded by the drug's maker.^[7]

Here's the catch for this article. Those numbers describe the approved product at the studied dose. They can't tell you how a compounded version, with its own ingredients and dosing, would perform. For the semaglutide basics, see our semaglutide injections guide, and for tirzepatide, our tirzepatide injections guide.

What are the side effects and risks of compounded GLP-1s?

The risks include the known side effects of semaglutide and tirzepatide, plus the extra uncertainty that comes with a drug the FDA hasn't reviewed. The safety details below come from the FDA labels for the approved products, so talk through which warnings apply to you with a licensed clinician.

Boxed warning and who shouldn't use these medicines

Both labels carry a boxed warning, the FDA's strongest kind, about thyroid C-cell tumors. In rodents, semaglutide caused these tumors at clinically relevant exposures, and it hasn't been determined whether it does in humans.^[6] Tirzepatide's label says the same about rats.^[8]

Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and in anyone who has had a serious allergic reaction to the medicine or its ingredients.^[6][8] Report a lump in the neck, trouble swallowing, shortness of breath or lasting hoarseness.^[8]

Pregnancy matters too. Both labels say these medicines may harm a baby and should be stopped once pregnancy is recognized, and the semaglutide label says to stop at least 2 months before a planned pregnancy.^[6][8]

Common side effects

Stomach trouble is the headline. Here's what the approved semaglutide label reports for the 2.4 mg weight-loss dose in trials of up to 68 weeks, as the percent of adults affected. Compounded versions weren't part of these numbers.^[6]

Side effect	On semaglutide 2.4 mg	On placebo
Nausea	44%	16%
Diarrhea	30%	16%
Vomiting	24%	6%
Constipation	24%	11%

Some people stopped treatment because of side effects: 6.8% on semaglutide versus 3.2% on placebo.^[6] Nausea, vomiting and diarrhea were the most common reasons.^[6]

Tirzepatide's label shows a similar pattern over up to 72 weeks. Across the studied doses, nausea hit 25% to 29% of people versus 8% on placebo, diarrhea 19% to 23% versus 8%, vomiting 8% to 13% versus 2%, and constipation 11% to 17% versus 5%.^[8] Between 4.8% and 6.7% stopped because of side effects, versus 3.4% on placebo.^[8] Most nausea, vomiting and diarrhea came during dose increases and eased over time.^[8]

Other warnings on the labels

• Pancreatitis and gallbladder disease: both labels list them. In semaglutide's weight-loss trials, gallstones were reported in 1.6% of adults versus 0.7% on placebo.^[6][8]
• Low blood sugar: the risk is higher if you also take insulin or a sulfonylurea, and a clinician may lower those doses.^[6][8]
• Kidney injury, serious allergic reactions, eye changes with diabetes, heart rate increase: all appear in the labels' warnings and precautions. The heart rate warning is on the semaglutide label.^[6][8]
• Severe stomach reactions: neither medicine is recommended in people with severe gastroparesis.^[6][8]
• Surgery or sedation: tell your care team before any procedure, because of a risk of food or liquid getting into the lungs under anesthesia.^[6][8]
• Other medicines: slower stomach emptying can change how some pills are absorbed. Tirzepatide can make birth control pills less reliable, so the label advises a non-oral method or a barrier method for 4 weeks after starting and after each dose increase. Neither should be combined with another GLP-1 product.^[6][8]

Risks specific to compounding, and when to get help

Because the FDA doesn't review these products first, quality can vary. The FDA has flagged dosing errors, shipments that arrive warm, fraudulent labels, and reports linked to doses above the approved label amounts.^[1] If your medicine comes in a multi-dose vial, the FDA says to throw it out 28 days after first use even if some is left, and to use a new needle and syringe every time.^[1] Don't use anything that arrives warm or poorly chilled.^[1]

Call your clinician the same day if vomiting or diarrhea keeps you from holding down fluids, since dehydration can hurt your kidneys.^[8] Stop the medicine and get help right away for severe stomach pain that won't go away, which can spread to your back.^[8] Tell your clinician promptly about upper belly pain with fever, yellow skin or eyes, or clay-colored stools, and about vision changes or a neck lump.^[6][8] Swelling of the face, lips, tongue or throat, a severe rash, or trouble breathing is a 911 situation.^[8] If you take too much, call Poison Help at 1-800-222-1222.^[8] You can also report side effects or product problems to the FDA's MedWatch program.^[1]

How can you spot a trustworthy telehealth provider?

Check for a real screening, a prescription from a licensed clinician, and honest language about what the medicine is. The FDA's own red-flag list is a good place to start.^[1]

Be wary if a company:

• Claims its compounded drug is the same as an FDA-approved one.
• Offers deep discounts or prices that seem too good to be true.
• Sends medicine that looks different from what was pictured, or arrives damaged or without instructions.
• Skips screening and a prescription from a licensed doctor.
• Has no licensed doctor available to answer questions after your medicine arrives.^[1]

The FDA also advises getting a prescription from your doctor and filling it at a state-licensed pharmacy.^[1] If you're weighing us, our guide on how to verify ShopMedRx and what to check before you choose walks through it.

Getting a compounded GLP-1 through ShopMedRx

If you decide to explore it, here's how it works. There's no membership fee, pricing is shown up front on each product page, and you can cancel any time. We don't bill insurance, and products are HSA/FSA reimbursable. ShopMedRx is available in all 50 states plus DC, though some services may not be available everywhere.

1. You complete a short online health assessment.
2. A licensed clinician in your state reviews it and prescribes only if it's clinically appropriate. A prescription is not guaranteed, and you aren't charged for medication if you aren't prescribed.
3. If you're prescribed a compounded medication, a state-licensed 503A compounding pharmacy prepares it and ships it to you in unmarked packaging.

GLP-1 plans also include free 1-on-1 care coaching. Compounded medications are not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality.^[2]

You can see current pricing on the semaglutide injection page, the tirzepatide injection page or the oral semaglutide page. The how it works page has the full walkthrough. When you're ready, you can check if you qualify online.

Bottom line

A compounded GLP-1 is a pharmacy-prepared semaglutide or tirzepatide medicine made for one patient, and it isn't FDA-approved or FDA-reviewed. The rules have tightened, the trial results belong to approved products, and the risks are real. A clear conversation with a licensed clinician about your individual situation is the best place to start.

Frequently asked questions

Is a compounded GLP-1 the same as the FDA-approved drug?

No. Compounded drugs are not FDA-approved, so the FDA doesn't review them for safety, effectiveness or quality before patients get them.^[2] The FDA also lists claims that a compounded drug is the same as an approved one as a telehealth red flag.^[1] They may share an active ingredient, but they're different products with different oversight.

Is compounded semaglutide or tirzepatide still allowed?

Only within limits. After the shortages ended, the shortage exception that let pharmacies make copies closed.^[4] FDA guidance still recognizes compounding when a prescriber documents a significant difference for an individual patient.^[3] Whether that applies to you is a licensed clinician's decision.

Do I need a prescription for a compounded GLP-1?

Yes. Compounding of this kind requires a valid prescription for an identified individual patient.^[2] The FDA advises getting the prescription from your doctor and filling it at a state-licensed pharmacy.^[1] A seller that skips screening and a licensed prescriber is a red flag.

Is a compounded GLP-1 riskier than an approved one?

The FDA says compounded drugs pose a higher risk than approved ones, because they don't get premarket FDA review.^[5] It has flagged dosing errors and improper storage with compounded GLP-1s.^[1] Asking about the pharmacy, storage and written directions is a sensible step.

Were compounded GLP-1s studied in the weight-loss trials?

No. The major trials, such as STEP 1, studied an FDA-approved semaglutide product in adults without diabetes. Adults lost 14.9% of their body weight on average over 68 weeks, versus 2.4% on placebo.^[7] Those are group averages, and individual results may vary.

Can I use HSA or FSA funds for a compounded GLP-1?

ShopMedRx products are HSA/FSA reimbursable, but we don't bill insurance, so check with your plan about what it will reimburse. Pricing is shown up front on each product page, and there's no membership fee.

Talk to a licensed clinician

Before you start, stop or change any treatment, talk to a licensed clinician about your health history and other medicines. If you would like to see whether treatment from ShopMedRx could be appropriate for you, you can check if you qualify.

Important information

• This article is for general education and is not medical advice. Talk to a licensed clinician before starting, stopping or changing any treatment.
• All medications available through ShopMedRx are prescription only and are prescribed only if appropriate after a licensed clinician's review.
• Most medications we offer are compounded. Compounded medications are not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. They are not the same as, or generic versions of, brand-name drugs.
• Individual results may vary. Nothing in this article promises a specific result.
• Prescriptions are written by clinicians licensed in the patient's state, only when clinically appropriate. All prescriptions are filled by state-licensed 503A compounding pharmacies.

Sources

1. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026-10. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
2. U.S. Food and Drug Administration. Human Drug Compounding Laws. 2024-12. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
3. U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (Guidance for Industry). 2018-01. https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf
4. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2025-02. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
5. U.S. Food and Drug Administration. Compounding when Drugs are on FDA's Drug Shortages List. 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-when-drugs-are-fdas-drug-shortages-list
6. DailyMed (National Library of Medicine). Label: WEGOVY (semaglutide) injection and tablets, prescribing information. 2026-06. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
7. New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021-03-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
8. DailyMed (National Library of Medicine). Label: ZEPBOUND (tirzepatide) injection, prescribing information. 2026-09. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b